Asimadoline may see use in treating Irritable Bowel Syndrome sooner thanks to being “fast tracked” by the FDA.

Tioga Pharmaceuticals announced via press release that they have received fast track status from the FDA on their drug Asimadoline. Asamadoline is an agonist which binds to the kappa opioid receptor. The kappa opioid receptors reside in the brain, spinal cord & peripheral nervous system. Asimadoline is targeted to work on the peripheral nervous system, while avoiding the brain due to it’s inability to cross past the blood brain barrier. Clinical trials of Asimadoline show that the drug is helpful with treating pain, discomfort & urgency in those with diarrhea predominant IBS symptoms. Continue reading “Asimadoline IBS Drug Gets Fast Tracked By FDA” »

recent study coming out of Penn State University is showing more positive results for the opiod antagonist Naltrexone. They studied 40 people who had active Crohn’s Disease and gave them a daily, orally administered, 4.5mg dose of Naltrexone or a placebo. Eighty percent of those treated with Naltrexone stated that they had improvement in their symptoms, 78% had confirmed benefit via endoscopy & 33% went into remission. Naltrexone had a huge lead against placebo, for example while 33% went into remission on Naltrexone, only 8% went into remission while taking the placebo. Overall it looks like Naltrexone may be of great help to those with Crohn’s Disease. Hopefully the positive results will continue as more studies are done.

For those with Irritable Bowel Syndrome, Naltrexone might be of use as well. There is another opioid based antagonist that’s being studied called Mu-Delta. It’s somewhat different than Naltrexone & the manufacturer is focusing on Irritable Bowel Syndrome specifically.

More Info:

The FDA recently granted fast-track status for the drug MuDelta which was created by Furiex Pharmaceuticals. MuDelta is a combo delta opioid receptor agonist(stimulates) and a mu receptor antagonist(blocks stimulation). The drug has similarities to another opioid receptor drug Naltrexone, however Naltrexone is purely a opioid receptor antagonist for the mu, kappa & to a small extent delta receptors. It does not have agonist properties and thus doesn’t stimulate any of the receptors.

Continue reading “Furiex’s New Irritable Bowel Syndrome Drug “MuDelta”” »

Copyright © 2024 The Digestion Blog - Mark & Gabriel Hedges.

Privacy Policy